Quantcast
Last updated on April 21, 2014 at 11:58 EDT

Latest Tacrolimus Stories

2010-07-28 02:00:00

TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan; President & CEO: Masafumi Nogimori) announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product...

2010-07-02 07:00:00

MORRISTOWN, N.J., July 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules. Watson intends to begin shipping the product immediately. Prograf ® 5 mg had total U.S....

2010-06-24 16:17:11

C2 monitoring and age are key factors Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD). The 1-year survival rate after liver transplantation has dramatically...

2010-03-04 10:12:00

DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. After receiving reports of dispensing errors between KAPIDEX...

2009-12-06 17:35:00

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT). The...

2009-11-10 00:30:00

CAMBRIDGE, Mass. and TOKYO, Nov. 10 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand. Linaclotide is currently in Phase 3 clinical development in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and...

2009-10-05 10:56:55

Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, said researchers at the Thomas E. Starzl Transplantation Institute in a study published in the October issue of Annals of Surgery. Led by Kareem Abu-Elmagd, M.D., Ph.D., director, Intestinal Rehabilitation and...

2009-08-12 18:35:00

DEERFIELD, Ill., Aug. 12 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's (FDA) decision regarding its Citizen Petition. The company's requests have been denied by the U.S. District Court in Washington, D.C. The company is disappointed in the court's decision and is currently evaluating its next course of action. The Citizen...

2009-08-10 22:52:00

DEERFIELD, Ill., Aug. 10 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has substantially denied the company's Citizen Petition to ensure the safe and effective use of immunosuppressants (also called anti-rejection medications) used to prevent rejection in organ transplant patients. In their petition, Astellas requested that the FDA take additional measures to protect transplant recipients, a unique and vulnerable...

2009-08-04 14:00:00

Underweight and very severely obese patients at riskA recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation surgery. These findings, from the largest known observation of liver transplantation at the extremes of BMI, are published in the August issue of Liver Transplantation, a journal published by John Wiley & Sons on...